- Home
- CTM vs BIVI Comparison
CTM vs BIVI Comparison
Compare CTM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTM
- BIVI
- Stock Information
- Founded
- CTM 2019
- BIVI 2013
- Country
- CTM United States
- BIVI United States
- Employees
- CTM N/A
- BIVI N/A
- Industry
- CTM EDP Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- CTM Technology
- BIVI Health Care
- Exchange
- CTM Nasdaq
- BIVI Nasdaq
- Market Cap
- CTM 54.7M
- BIVI 49.8M
- IPO Year
- CTM N/A
- BIVI N/A
- Fundamental
- Price
- CTM $0.84
- BIVI $1.48
- Analyst Decision
- CTM
- BIVI Strong Buy
- Analyst Count
- CTM 0
- BIVI 1
- Target Price
- CTM N/A
- BIVI $30.00
- AVG Volume (30 Days)
- CTM 4.6M
- BIVI 596.3K
- Earning Date
- CTM 03-20-2025
- BIVI 02-11-2025
- Dividend Yield
- CTM N/A
- BIVI N/A
- EPS Growth
- CTM N/A
- BIVI N/A
- EPS
- CTM N/A
- BIVI N/A
- Revenue
- CTM $45,555,964.00
- BIVI N/A
- Revenue This Year
- CTM $29.25
- BIVI N/A
- Revenue Next Year
- CTM N/A
- BIVI N/A
- P/E Ratio
- CTM N/A
- BIVI N/A
- Revenue Growth
- CTM 3.12
- BIVI N/A
- 52 Week Low
- CTM $0.12
- BIVI $1.04
- 52 Week High
- CTM $2.83
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- CTM 45.52
- BIVI 32.72
- Support Level
- CTM $0.92
- BIVI $1.45
- Resistance Level
- CTM $1.20
- BIVI $1.88
- Average True Range (ATR)
- CTM 0.14
- BIVI 0.16
- MACD
- CTM -0.01
- BIVI -0.01
- Stochastic Oscillator
- CTM 30.42
- BIVI 5.08
About CTM Castellum Inc.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.